 In support of planned Investigational New Drug application for lechlemer, Napo Pharmaceuticals, Jaguars wholly owned subsidiary, received comprehensive animal toxicity preclinical services supported by the National Institute of Allergy and Infectious Diseases for four studies SAN FRANCISCO, CA ACCESSWIRE August 17, 2021 Napo Pharmaceuticals, Inc. Napo, the wholly-owned subsidiary of Jaguar Health, Inc. NASDAQ:JAGX Jaguar or the Company, announced today the completion of an additional preclinical toxicology study intended to support continued development of NP-300 lechlemer for the symptomatic relief of diarrhea from cholera and other infectious diarrheal conditions. The study findings support the Investigational New Drug IND application Napo plans to file for lechlemer for this indication in the first half of 2022. 